In SMAD4‐null BxPC‐3 cells, ITGAV KO reduced ERK phosphorylation, indicating an alternate signaling pathway and potential compensatory role for MAPK/ERK signaling in supporting tumor cell motility when TGF‐β/SMAD signaling is impaired [58, 59]. Here, ITGAV is linked to neoplasm.